|
MediVas, LLC
Announces Positive Preclinical Ferret Data Against H5N1
San Diego, CA -- October 18, 2006 -- MediVas, LLC, today announced
promising data from a preclinical H5N1 vaccine study in ferrets performed at
Battelle Memorial Institute’s Medical Research and Evaluation Facility in
Columbus, Ohio. For this study, MediVas utilized its novel, synthetic subunit
vaccine, which provides an alternative to traditional egg-based vaccines. The
vaccine used the company’s patented biodegradable polymer technology in a
particle form with purified recombinant hemagglutinin (HA) and nucleoprotein
(NP) from the A/Vietnam/1203/2004 virus. This technology allows MediVas to
produce a vaccine against any mutated influenza virus in as short as five weeks.
Commenting on the results, Kenneth W. Carpenter, MediVas’ President and CEO
said, “These outstanding results represent a significant achievement in the
development of our next-generation pandemic flu vaccine. These data validate
our novel technology and, in particular, our lead intranasal formulation, which
showed a 100% survival rate, presents a meaningful advance in vaccine
technology. With the high antibody response and exceptional survival results
achieved across all formulations in this study, coupled with our ability for low
cost manufacture, storage and transport of our subunit vaccines, MediVas is
poised to deliver a breakthrough in the fight against avian and seasonal flu.”
About MediVas: Since its founding in 1998, MediVas
has had one simple goal - to change the way that pharmaceuticals are delivered.
From small molecule drugs to whole proteins, MediVas has developed a novel
platform technology that provides solutions to meet each challenge. MediVas
polymers are the first of a new generation of absorbable and biocompatible drug
and biologic delivery platforms. MediVas is utilizing its novel polymer
technology in collaboration with some of the world's largest pharmaceutical and
medical device companies, as well as our own internal product development
efforts. Using this platform technology, MediVas is currently focusing its
development efforts on the delivery of biologics.
Contact:
MediVas, LLC
Victor E. Vilaplana
Director, Business Development
(858) 622-2005
vvilaplana@medivas.com © MediVas, LLC
|